CSPHF (CStone Pharmaceuticals) Accounts Payable: $10.96 Mil (As of Dec. 2025)


CSPHF CStone Pharmaceuticals CSPHF
44 GF Score
Price $0.59
GF Value $0.13
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals Accounts Payable?

CStone Pharmaceuticals CSPHF -14.46% 44 Accounts Payable is $10.96 Mil as of Dec. 2025. GuruFocus rates CSPHF with a GF Score™ of 44/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 7 warning signs investors should review.

CStone Pharmaceuticals's Accounts Payable for the quarter that ended in Dec. 2025 was $10.96 Mil.

CStone Pharmaceuticals's quarterly Accounts Payable declined from Dec. 2024 ($46.43 Mil) to Jun. 2025 ($29.54 Mil) and declined from Jun. 2025 ($29.54 Mil) to Dec. 2025 ($10.96 Mil).

CStone Pharmaceuticals's annual Accounts Payable increased from Dec. 2023 ($34.51 Mil) to Dec. 2024 ($46.43 Mil) but then declined from Dec. 2024 ($46.43 Mil) to Dec. 2025 ($10.96 Mil).

CStone Pharmaceuticals Accounts Payable Related Terms

CStone Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for CStone Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CStone Pharmaceuticals Accounts Payable Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.05 41.66 34.51 46.43 10.96

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.51 0.00 46.43 29.54 10.96
CSPHF
44GF Score
CStone Pharmaceuticals CSPHF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CStone Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $10.96 Mil mean?
CStone Pharmaceuticals (CSPHF) has a Accounts Payable of $10.96 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on CStone Pharmaceuticals and its competitors.
Is CStone Pharmaceuticals' Accounts Payable too high?
CStone Pharmaceuticals' current Accounts Payable is $10.96 Mil. Overall, CStone Pharmaceuticals has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CStone Pharmaceuticals' Accounts Payable compare to VRTX and REGN?
CStone Pharmaceuticals' Accounts Payable of $10.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on CStone Pharmaceuticals and its competitors. CStone Pharmaceuticals's current Accounts Payable is $10.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CStone Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CStone Pharmaceuticals (CSPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.59 — trading 357.3% above its estimated fair value. The current Accounts Payable is $10.96 Mil. CStone Pharmaceuticals' overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For CStone Pharmaceuticals (CSPHF), the current Accounts Payable is $10.96 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CStone Pharmaceuticals (CSPHF) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of $0.59 is trading 357.3% above its estimated GF Value™ of $0.13. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CSPHF:

  • Accounts Payable: $10.96 Mil
  • GF Value™: $0.13 vs. price of $0.59 (357.3% above fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the CSPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CStone Pharmaceuticals Business Description

Other Exchanges 02616:Hong KongPH4:Germany
Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
44GF Score

Get the complete analysis for CSPHF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.59
Price
$0.13
GF Value